Atorvastatin API Manufacturers & Suppliers

Atorvastatin (CAS 134523-00-5) is an orally administered HMG‑CoA reductase inhibitor indicated for the management of primary hyperlipidemia, mixed dyslipidemia, hypertriglyceridemia, primary dysbetalipoproteinemia, and familial hypercholesterolemia. It is also used to reduce cardiovascular event risk in patients with established atherosclerotic disease or multiple risk factors, including those with type 2 diabetes. Preventive applications include lowering the incidence of myocardial infarction, stroke, angina, and revascularization procedures in both primary and secondary prevention contexts.

The compound is a diphenylpyrrole derivative and is active without metabolic conversion. Atorvastatin competitively inhibits hepatic HMG‑CoA reductase, decreasing synthesis of mevalonate and downstream cholesterol intermediates. Reduced intracellular cholesterol upregulates LDL receptors and enhances clearance of circulating LDL. The drug lowers total cholesterol, LDL‑C, non‑HDL‑C, apolipoprotein B, very‑low‑density lipoproteins, and triglycerides, while producing modest increases in HDL‑C. Additional experimental data show anti-inflammatory and endothelial‑modulating properties, although these effects are not considered primary drivers of therapeutic benefit.

Oral absorption is followed by extensive first-pass hepatic uptake. Atorvastatin is a substrate of CYP3A4 and hepatic transporters including OATP1B1, OATP1B3, and P‑glycoprotein. Metabolism generates active ortho‑ and para‑hydroxy metabolites. Elimination occurs mainly via biliary pathways, with minimal renal excretion.

Safety considerations include dose-dependent myopathy and rare rhabdomyolysis, particularly when used with interacting CYP3A4 inhibitors or transporter inhibitors. Transaminase elevations occur infrequently but warrant monitoring. Statins can increase glucose and HbA1c, and rare endocrine effects have been reported. Observed reductions in ubiquinone levels and variable effects on lipoprotein(a) may have uncertain clinical significance.

Atorvastatin is widely recognized under brands such as Lipitor in various markets. For API procurement, reliable suppliers should provide evidence of compliance with pharmacopoeial standards, validated control of stereochemistry and impurities, and robust data supporting stability, particle size distribution, and compatibility with intended formulation processes.